On one side, some asked whether the therapy should be discontinued during SARS-Cov-2 pandemic [17, 37] because COVID-19 was strongly associated with hypertension, which is frequently treated with ARBs and ACE inhibitors [2–4]. This evidence concerns the gene ACE and hypertensive disorder.